gefitinib has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danilov, AV; Hamilton, BJ; Jones, JD; Rigby, WFC; Skopelja-Gardner, S | 1 |
| Banerji, V; Dielschneider, RF; Gibson, SB; Johnston, JB; Li, H; Marshall, AJ; Noh, E; Xiao, W; Yoon, JY | 1 |
2 other study(ies) available for gefitinib and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cell Adhesion; Cell Adhesion Molecules; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Receptors, IgG; Rituximab; Signal Transduction; ZAP-70 Protein-Tyrosine Kinase | 2017 |
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
Topics: Cell Survival; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Quinazolines; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2014 |